On February 6, 2017, the Food and Drug Administration revised its frequently asked questions about DBT and MQSA training requirements so that manufacturer-specific DBT training is no longer required. The guidance states that personnel need only obtain training on one DBT system, or obtain general DBT training, to meet the new modality training requirement. However, since some features are unique to each DBT system, personnel are encouraged to pursue additional training on those features of their unit(s).

For more information, see FDA Frequently Asked Questions about DBT and MQSA Training Requirements.